Analyst Information


David Amsellem

Sr. Research Analyst

David Amsellem

David Amsellem is a managing director and senior research analyst at Piper Sandler covering specialty pharmaceuticals. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-08 and a senior associate on the biotechnology equity research team from 2003-06. Amsellem has more than 15 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Amsellem earned a bachelor’s degree from Cornell University.

Universe Coverage:
Healthcare:   Specialty Pharmaceuticals
AMRXAmneal Pharmaceuticals Inc.
AMPHAmphastar Pharmaceuticals, Inc.
AVDLAvadel Pharmaceuticals plc
BHCBausch Health Companies
CARACara Therapeutics Inc.
COLLCollegium Pharmaceutical, Inc.
EGRXEagle Pharmaceuticals Inc.
ENDPEndo International plc
EVFMEvofem Biosciences, Inc.
HRMYHarmony Biosciences Holdings, Inc.
HZNPHorizon Therapeutics
ITCIIntra-Cellular Therapies, Inc.
IRWDIronwood Pharmaceuticals, Inc.
JAZZJazz Pharmaceuticals plc
MYLMylan N.V.
NBIXNeurocrine Biosciences Inc.
OPTNOptiNose, Inc.
OGNOrganon & Co.
PCRXPacira Biosciences, Inc.
RVNCRevance Therapeutics, Inc.
SUPNSupernus Pharmaceuticals, Inc.
TEVATeva Pharmaceutical Industries Limited
VYNEVYNE Therapeutics Inc.
XERSXeris Pharmaceuticals, Inc.